AbbVie Boosts Outlook for Two Key Drugs After Beating Profit, Sales Estimates

Key TakeawaysAbbVie Inc. reported profit and sales that beat estimates, and raised its guidance on two of its key drugs.The pharmaceutical company's revenue was fueled by immunology treatments Skyrizi and Rinvoq.AbbVie said it now anticipates Skyrizi and Rinvoq will bring in sales of $27 billion by 2027.AbbVie Inc. (ABBV) shares traded near their all-time high Friday as the pharmaceutical company posted better-than-expected results and raised its sales forecast for two of its key medicines.AbbVie reported f ...